{
  "url": "https://www.law.cornell.edu/regulations/new-york/14-NYCRR-710.5",
  "title": "N.Y. Comp. Codes R. & Regs. Tit. 14 ยง 710.5 - Procedures of the surrogate decision-making committee program and panels",
  "content": "N.Y. Comp. Codes R. & Regs. Tit. 14 ยง 710.5 - Procedures of the surrogate decision-making committee program and panels\n\nState Regulations\n(a) Upon receipt of\nthe declaration, the procedures of the program staff are as follows: (1)\n\nThe program staff or its designee shall\nsend a copy of the declaration to the following interested parties as set forth\nin the declaration: the patient; any authorized surrogate outlined in Mental\n\nHygiene Law section 80.07(b) for decisions regarding major medical treatment; any authorized surrogate as outlined Surrogate's Court Procedure Act section\n1750-b(1) (a) (ii) (B) for decisions to withhold or withdraw lifesustaining\ntreatment; correspondent, if known; the director of the patient's residential\nfacility or such director's designee; and the Mental Hygiene Legal Service\n(MHLS) departmental office that serves the same region as the patient's county\nof residence. (2)\n\nCopies of the\ndeclaration shall be sent along with a notice of hearing which shall inform\nrecipients of the procedures of the panel, including the opportunity for the\nrecipient to be heard. The Justice Center shall determine the venue or format\nfor the hearing based on the totality of the circumstances, which may include\nvideo conference, telephone, or other technology that allows for remote\nparticipation. In making such determination, the Justice Center shall consider\nany requests for an in-person hearing from participants. (3)\nA surrogate, or correspondent who does\nnot respond to the notice or who submits a signed waiver for the proceeding\nshall be deemed to be willing to allow the panel to proceed; provided, however, that parents of minors who have not had their parental rights terminated must\nsubmit a waiver to indicate their willingness to allow the panel to consider\nthe declaration. (4)\n\nThe hearing\nshall be scheduled no earlier than five days after the notice of hearing is\nsent by the program staff to the interested parties set forth in (a)(1) of this\nsection, except where medical or dental circumstances require a more immediate\nhearing, or where consent to conduct a more immediate hearing has been obtained\nfrom all of the interested parties. When the interested parties have consented\nto a more immediate hearing, a hearing shall be scheduled at the earliest\nconvenience. (5)\n\nThe program staff\nshall assign the declaration to one of the committee's panels and shall send a\ncopy of the declaration and any supporting documents to the members of the\ndesignated panel. Confidential information regarding AIDS, HIV infection or\nrelated virus or illness shall be sent to the panel and to MHLS on behalf of\nthe patient. Such confidential information shall also be sent to any other\nperson only if necessary to provide for appropriate review by the committee; provided, however, that any such disclosure shall include a notice of the\nconfidential nature of the information and the penalties for unauthorized\ndisclosure as provided for by PHL article 27-F. (6)\n\nThe panel proceedings may be conducted\nwith only three persons. Provided, however, if a program staff receives\nreasonable notice at least 48 hours prior to the hearing that a panel member\nwill not be able to attend a panel hearing, program staff shall take reasonable\nsteps to secure an appropriate replacement panel member. (i) Repealed. (ii)\n\nRepealed. (7)\n\nPrior to the date of the hearing, the\ndeclaration shall be preliminarily reviewed by program staff to ascertain\nwhether additional information may be necessary to assist the panel in\ndetermining the patient's need for surrogate decision-making and in determining\nwhether the patient's best interests will be served by the proposed major\nmedical treatment or end-of-life decision on the patient's behalf. The program\nstaff may request and shall, notwithstanding any other law to the contrary, be\nentitled to receive from any physician, mental hygiene facility, health care\nfacility or person licensed to render health care, any information which is\nrelevant to the patient's need for surrogate decision-making or the proposed\ndecision. Such information may include, among other things: facts regarding the\npatient's parents, spouse, adult child, legal guardians, or other authorized\nsurrogates; facts and professional opinions regarding the patient's capacity to\nmake the proposed decision; and facts and professional opinions regarding\nwhether the proposed major medical treatment decision is in the patient's best\ninterests. (b) The\ngeneral procedures of the hearing are as follows: (1)\n\nThe hearing shall be conducted by the\npanel. Recipients of the declaration, as well as any other person requested by\nthe patient to appear on their behalf, shall have the right to be present and\nbe heard. (2)\n\nThe facility where\nthe patient resides shall, to the extent possible, ensure the presence of the\npatient at the hearing unless the declaration contains a certification by a\nphysician, podiatrist, or dentist that the patient is unable for medical\nreasons to attend the hearing or unless it is a declaration regarding the\nwithdrawal or withholding of life-sustaining treatment. To the extent\npracticable, the patient should be accompanied by a person who is personally\nfamiliar with the patient, their condition and their history. If the patient is\nunable to attend the hearing or if it is a declaration regarding the withdrawal\nor withholding of lifesustaining treatment, the panel members shall either\nobserve and interview the patient, or the program staff or a designee shall\ndesignate at least one panel member to observe and interview the patient prior\nto the commencement of the hearing. (3)\n\nThe panel shall be empowered to\nadminister oaths to and to take testimony from any person who might assist the\npanel in making its decision. (4)\n\nThe panel shall be empowered to conduct its proceeding via telephone conference\ncalls or any other technology that allows for remote participation in\nappropriate cases, including but not limited to cases in which: (5)\n\nConfidential information regarding AIDS, HIV infection or related virus or illness may be disclosed as determined by the\npanel during the hearing if relevant to the determination of capacity or\ndetermination of need for major medical treatment; provided, however, that\nparticipants shall be provided with a notice of the confidential nature of the\ninformation and the penalties for unauthorized disclosure as provided for by\narticle 27-F of the PHL. (6)\n\nFormal\nrules of evidence shall not apply to the panel proceedings. (7)\n\nIf at any time during the pendency of a\nproceeding, a patient, parent, spouse, adult child, legal guardian, or other\nsurrogate who is legally authorized to consent to or refuse such treatment on\nthe patient's behalf, objects to the panel acting upon the declaration, the\nproceedings regarding such patient shall cease. Any such person's objection\nshall be made part of the record. (8)\n\nWhen the proposed major medical treatment\ndecision consists of more than one medical, surgical or diagnostic intervention\nor procedure, the panel shall be empowered to consider and give or refuse\nconsent for each proposed intervention or procedure separately. If the panel\ngives consent for one or more, but not all, of the proposed interventions or\nprocedures, the panel's record of its determination shall indicate consent or\nrefusal for each intervention or procedure separately. (9)\n\nWhen the proposed end-of-life decision\nconsists of more than one medical, surgical or diagnostic intervention or\nprocedure, the panel shall be empowered to consider and give or refuse consent\nfor each proposed intervention or procedure separately. If the panel gives\nconsent for one or more, but not all, of the proposed interventions or\nprocedures, the panel's record of its determination shall indicate consent or\nrefusal for each intervention or procedure separately. (10)\n\nWhere practicable, the panel shall reach\nits determination immediately and provide a copy of the determination to the\ninterested parties immediately after the hearing. Notice of this determination\nmay be given by any means that will provide timely or reliable notice. The\ngiving of such notice shall be made part of the record. (11)\n\nAt the hearing, the panel shall be\nempowered to: (i) order an independent\nassessment of the patient, or order information concerning the patient, including obtaining an independent opinion, where such independent assessment\nor opinion is determined to be necessary by the panel chairperson; or\n(ii)\nconsult with any other person who might\nassist in such a determination of the best interests of the patient, including\nascertainment of the personal beliefs and values of the\npatient. (12)\n\nNothing in\nthis section shall be interpreted to authorize ex parte communications during\nthe hearing or consideration of materials, information, or opinions not\npresented formally at the hearing. (c) The panel's determination of the\npatient's need for surrogate decision-making shall be made in accordance with\nthe following provisions: (1)\n\nIn hearings\nregarding proposed major medical treatment decisions, the panel shall determine\nwhether there is clear and convincing evidence that the patient: lacks the\ncapacity to make the proposed major medical treatment decision; and does not\nhave a parent, spouse, adult child, other authorized surrogate, or legal\nguardian, who is legally authorized, available and willing to make such a\ndecision. Clear and convincing evidence is evidence that is highly reliable and\nupon which reasonable persons may rely with confidence in the probability of\nits correctness. (2)\n\nIn determining\nwhether the patient lacks the capacity to make the proposed major medical\ntreatment decision, the panel shall consider whether the patient is unable to\nadequately understand and appreciate the nature and consequences of the\nproposed major medical treatment decision, including: (i) the burdens of the treatment to the\npatient in terms of pain and suffering outweighing the benefits, or whether the\nproposed treatment would merely prolong the patient's suffering and not provide\nany net benefit; (ii)\nthe degree, expected duration and constancy of pain with and without treatment, and the\npossibility that the pain could be mitigated by less intrusive forms of medical\ntreatment including the administration of medications; (iii)\nthe likely prognosis, expectant level\nof functioning, degree of humiliation, and dependency with or without the\nproposed major medical treatment; and\n(iv)\nthe evaluation of treatment options, including non-treatment, and their benefits and risks compared to those of the\nproposed major medical treatment decision. (3)\n\nIn hearings regarding the proposed\nwithholding or withdrawal of life-sustaining treatment, the panel shall\ndetermine whether there is clear and convincing evidence as defined in (c)(1)\nof this section that the patient is in need of surrogate decision-making by\nconsidering the certification by the attending physician and the consulting\nphysician or licensed psychologist as set forth in Part 710.4(c)(2) and\nconsidering each of the factors set forth in the declaration. (4)\n\nUnless three panel members concur in the\ndetermination that the patient is in need of surrogate decision-making, the\npatient shall be deemed not to need surrogate decision-making. (5)\n\nIn the event that the patient is deemed\nnot to need surrogate decision-making because they have the capacity to consent\non their own behalf, patient consent to or refusal of such treatment, if given, shall constitute legally valid consent or refusal therefor. No other consent\nshall be required by a provider of health services. (d) The panel's determination regarding the\nappropriateness of the proposed health care decision shall be made in\naccordance with the following provisions: (1)\n\nIn a hearing regarding proposed major medical treatment, if a patient has been\ndetermined by the panel to be in need of surrogate decision-making, the panel\nshall make a determination whether the proposed major medical treatment is in\nthe best interests of the patient based upon a fair preponderance of the\nevidence. A fair preponderance of the evidence is evidence that an issue is\nmore likely true than not. (2)\n\nIn a\nhearing regarding the proposed withholding or withdrawal of life-sustaining\ntreatment, if a patient has been determined by the panel to be in need of\nsurrogate decision-making, the panel shall make a determination whether the\nproposed end-of-life decision is in the best interests of the patient based\nupon a fair preponderance of the evidence as defined in (d)(1) of this section. Decisions to withhold or withdraw life-sustaining treatment pursuant to section\n1750-b of the SCPA shall include consideration of the following additional\nfactors: (i) the panel decision is not\nintended to permit suicide, assisted suicide or euthanasia; (ii)\nthe panel decision shall be based on the\npatient's qualifying medical condition, other than developmental disability, with recognition that a person with developmental disability is entitled to\nfull and equal rights, equal protection, respect, medical care and dignity\nafforded to persons without developmental disabilities and without any\nfinancial considerations as such may affect the health care provider or any\nother party. (3)\n\nAny\nevidence of an articulated preference by the patient concerning the proposed\ntreatment shall be given full consideration by the panel. (4)\n\nThe panel's consent to major medical\ntreatment shall state that any tissues or parts surgically removed may be\ndisposed of or preserved by the provider of health services in accordance with\ncustomary practice. (e) Effect of the panel determination\n(1)\n\nThe\npanel determination shall include the effective date and the expiration date. The panel may delay the effective date for up to five days in order to enable\nan objecting party to exercise the right of appeal. For all determinations\nregarding a decision to withhold or withdraw life-sustaining treatment, the\npanel shall not delay the effective date of its decision. (2)\nA copy of any panel determination shall\ncontain a statement describing the right to appeal and shall promptly be sent\nto the following parties: patient; other persons requested by the patient to\nappear on their behalf; declarant; patient's parent, spouse, adult child, legal\nguardian, other known authorized surrogates, and correspondents; the director\nof the patient's residential facility or designee; service coordination\nprovider; and MHLS. (3)\n\nIn the event\nthat a panel refuses to consent to a major medical treatment that may be\nconsidered life-sustaining, any party may submit a new declaration for\nconsideration as a declaration for the withholding or withdrawal of\nlife-sustaining treatment with the requisite certifications and supporting\ndocuments. (4)\n\nIn the event that a\npanel refuses to consent to the withholding or withdrawal of life-sustaining\ntreatment, any party may submit a new declaration for consideration as a\ndeclaration for surrogate decision-making for major medical treatment, with the\nrequisite supporting documents. (5)\n\nThe panel determination regarding the major medical treatment decision or the\nend-of-life decision shall constitute legally valid consent or refusal to such\ntreatment in the same manner and to the same extent as if the patient were able\nto consent or refuse on their own behalf. No other consent shall be required by\na provider of health services. (6)\nA panel determination that a patient is in need of surrogate decision-making\nfor the proposed major medical treatment decision shall not be valid for any\nfuture major medical treatment and shall not be construed or deemed valid for\nany other purpose or for any other future major medical treatment unless the\ndetermination applies to related or continuing treatment necessitated by the\noriginal treatment. No panel determination shall be valid after the expiration\ndate listed in the determination, except as provided for in section\n701.5\n(b)(4)(iii). (7)\nA panel determination that a patient is\nin need of surrogate decision-making shall not be construed or deemed to be a\ndetermination that such patient is impaired or incompetent or incapacitated\npursuant to article 81 of the MHL. (8)\n\nNo person shall be deemed to have failed\nto exhaust administrative remedies for commencing a legal action to obtain a\nmajor medical treatment decision because of the pending review of the case by a\npanel. (f) A record of the\ndeterminations and proceedings of the panel shall be made and retained for 10\nyears. Such record shall include any information, record, assessment, consultation, or amendment submitted to or considered by the panel. (1)\n\nThe Justice Center, any designee, and\neach member of the panel shall maintain the confidentiality of records as\nrequired by sections 33.13 and 80.07(c)(1) of the MHL, article 27-F of the\nPHL. (2)\n\nAll information, records, assessments, consultations or amendments submitted to or considered by the\npanel and the panel deliberations are not subject to the Freedom of Information\n\nLaw or the Open Meetings Law. Notes\nN.Y. Comp. Codes R. & Regs. Tit. 14\nยง\n710.5\n\nRenumbered\nfrom 710.4\n\nNew\n\nYork State Register November 28, 2018/Volume XL, Issue 48, eff. 11/28/2018\n\nAmended\n\nNew\n\nYork State Register February 12, 2025/Volume XLVII, Issue 06, eff. 2/12/2025\n\nState regulations are updated quarterly; we currently have two versions available. Below is a\ncomparison between our most recent version and the prior quarterly release. More comparison features will be added as we have more versions to compare. No prior version found.",
  "url_type": "regulation",
  "source_index": 38574
}